Literature DB >> 24935699

pDsRed-EGFPmtag-, an effective dual fluorescent reporter system for cell-based screens of premature termination codon.

Quan Shen1, Ping Guo1, Baofeng Chai2.   

Abstract

A large number of inherited diseases are caused by premature termination codon (PTC) mutations that lead to the degradation of mRNA template. In this report, we developed a dual fluorescent reporter that relied the feature of fluorescent protein coding region to express a fusion protein from pDsRed-EGFPmtag-. Expression of the fusion protein from a single reporter provides a sensitive approach for high-throughput screening of cell-specific PTC events in mixed cell cultures. Results from the read-through analysis of COS7 cells carrying the nonsense mutation pDsRed-EGFPmtag-Y445X treated by PTC 124 showed EGFP transcript level was increased in the COS7 cells treated by PTC124 in a dose-dependent manner. This novel reporter system was applicable to the majority of different PTC patterns and could be used to quantify efficiency of read-through within a single cell or select cells carrying PTC.

Entities:  

Keywords:  Dual fluorescent reporter; Premature termination codon (PTC); Read-through efficiency

Year:  2014        PMID: 24935699      PMCID: PMC4628933          DOI: 10.1007/s10616-014-9728-x

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  16 in total

1.  Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes.

Authors:  Valérie Allamand; Laure Bidou; Masayuki Arakawa; Célia Floquet; Masataka Shiozuka; Marion Paturneau-Jouas; Corine Gartioux; Gillian S Butler-Browne; Vincent Mouly; Jean-Pierre Rousset; Ryoichi Matsuda; Daishiro Ikeda; Pascale Guicheney
Journal:  J Gene Med       Date:  2008-02       Impact factor: 4.565

2.  Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.

Authors:  E R Barton-Davis; L Cordier; D I Shoturma; S E Leland; H L Sweeney
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 3.  Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy.

Authors:  L V Zingman; S Park; T M Olson; A E Alekseev; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

4.  Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.

Authors:  M Manuvakhova; K Keeling; D M Bedwell
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

5.  Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line.

Authors:  D M Bedwell; A Kaenjak; D J Benos; Z Bebok; J K Bubien; J Hong; A Tousson; J P Clancy; E J Sorscher
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice.

Authors:  Masayuki Arakawa; Masataka Shiozuka; Yuki Nakayama; Takahiko Hara; Masa Hamada; Shin'ichi Kondo; Daishiro Ikeda; Yoshikazu Takahashi; Ryuichi Sawa; Yoshiaki Nonomura; Kianoush Sheykholeslami; Kenji Kondo; Kimitaka Kaga; Toshio Kitamura; Yuko Suzuki-Miyagoe; Shin'ichi Takeda; Ryoichi Matsuda
Journal:  J Biochem       Date:  2003-11       Impact factor: 3.387

7.  Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment.

Authors:  L Bidou; I Hatin; N Perez; V Allamand; J-J Panthier; J-P Rousset
Journal:  Gene Ther       Date:  2004-04       Impact factor: 5.250

Review 8.  Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.

Authors:  Steven M Rowe; John P Clancy
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

9.  PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.

Authors:  Ming Du; Xiaoli Liu; Ellen M Welch; Samit Hirawat; Stuart W Peltz; David M Bedwell
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

10.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.

Authors:  Ming Du; Kim M Keeling; Liming Fan; Xiaoli Liu; Timea Kovaçs; Eric Sorscher; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.